[Treatment of pancreatic insufficiency with a preparation containing high lipase activity].
In vitro testing of lipase survival of Panzytrat 25,000 homogenized in Tris HCl buffer and Lundh meal stimulated gastric or duodenal contents demonstrated favorable stability of lipase of this new preparation in the protein and fat containing gastric and duodenal juices of patients with chronic pancreatitis. Later an open, intra-individually controlled study with two doses of Panzytrat 25000 (5 x 1 and 5 x 2 capsules/day) was performed in 10 patients with severe pancreatic steatorrhoea. A diet containing 70 g of fat/day was offered and the 3-day fat loss of collected stools was measured in the last 3 days of 5-day equilibration periods with and without replacement therapy. After these short-term periods, patients were treated with 5 x 1 capsules of the drug for one month and body weight increases as well as patient's appraisals were registered. Stool weight and fat loss maximally decreased already in response to the 5-day treatment with 5 x 1 capsules of drug and double dose of the preparation did not further decrease steatorrhoea in most cases except 2 patient. Disappearance of fat loss was achieved in 3 out of ten patients. Body weight of patients increased in most cases and their subjective evaluation was also favorable.
Pap
A
A
Fóvárosi Onkormányzat Szent Imre Kórház Budapest, II. Belgyógyaszati Osztály.
Szilágyi
V
V
Marosi
E
E
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008049:Lipase / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010194:Pancreatin / Q000494:pharmacology / Q000627:therapeutic use*; D010195:Pancreatitis / Q000188:drug therapy*
D005765:Gastrointestinal Agents; D010194:Pancreatin; D008049:Lipase
A pancreaselégtelenség kezelése egy magas lipázaktivitású pancreatinkészítménnyel.